Kiniksa Pharmaceuticals International (KNSA) reported a Q3 loss Tuesday of $0.18 per diluted share, narrower than a loss of $0.20 a year earlier.
Analysts surveyed by Capital IQ expected a profit of $0.10.
Revenue for the quarter ended Sept. 30 was $112.2 million, compared with $67 million a year earlier.
Analysts surveyed by Capital IQ expected $111.6 million.
The company expects 2024 Arcalyst net product revenue of between $410 million and $420 million, compared with the range of between $405 million and $415 million previously anticipated.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.